Best in Biotech 18 May 2023 Six women’s health companies you should know about …receptors outside the central nervous system (CNS), currently in development. Founded in 2009, the company has amassed a total of $53.7 million over 10 funding rounds. HERA Biotech Affecting around… May 18, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Noema Pharma raises $112 million in Series B financing Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new… March 8, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 17 Jul 2017 Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares …market.” Speaking to the broad reach of GPCRs, Marshall told me, “We’ve also built up significant expertise in the CNS area,” making the field a prime target for Heptares’ next… July 17, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jun 2024 Spotlight on Georgia’s biotech industry: Seven companies to know about in 2024 …stroke, subarachnoid hemorrhage, and treatment-resistant depression by developing small-molecule therapeutics for central nervous system (CNS) disorders. NeurOp’s technology focuses on N-methyl-D-aspartate receptor (NMDAR) antagonists, specifically targeting the GluN2B subunit. NMDARs… June 25, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2025 Top biotech deals in May 2025 …to combine this molecule with Biogen’s drug delivery platform to target diseases that affect the central nervous system (CNS). In exchange, the American startup will receive $16 million upfront and… June 2, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2018 A New Biotech Hopes to Bring Us the Next Generation of Rare Metabolic Disorder Drugs …on its clinical candidate, MIN-102, which is now in phase II/III clinical trials for the treatment of X-linked adrenoleukodystrophy and in preclinical development for other orphan CNS diseases.” TiVenture’s managing… February 20, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 26 May 2023 Could new Lyme disease tests help to prevent chronic infection? …years, or even a lifetime. When this happens, the disease is allowed to spread, potentially reaching the joints, heart and central nervous system (CNS), and can result in severe and… May 26, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies …aspects of clinical drug development. It acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them. TrialSpark’s current therapeutic areas of focus include rheumatology, dermatology, CNS, and cardiometabolic diseases…. October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 16 Dec 2025 Biotech in 2025: A retrospective …and more on whether genetics and biomarkers can finally make a difference in how depression and other central nervous system (CNS) disorders are treated. One of the most widely discussed… December 16, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the… August 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 20 Jul 2023 Beyond Biotech podcast 55: Inflammasomes …meaningful reductions. Neurofilament light chain (NfL), exclusively synthesized in the central nervous system (CNS), decreased by approximately 25% over seven days in the most inflamed subject and by 13% on… July 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s …be added to existing antibodies to generate a bispecific antibody (mAb²) that can cross the blood-brain barrier, as well as bind to specific targets within the CNS. Changes that occur… January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email